Skip to content
Companies

Xilis

Miniature tumor models that match patients to cancer drugs

Raised to date

$19.4M

of $19.4M offered across 1 Form D filing

Investors
9
Last filed
Apr 25, 2025

About

Xilis, Inc. is a biotech company focused on transforming cancer treatment through innovative technologies that enable personalized medicine. By leveraging its proprietary MicroOrganoSphere™ technology, Xilis offers tailored therapeutic solutions that match cancer patients with the most effective treatments based on their individual tumor biology.

Xilis stands out by creating microscale tumor models that closely mimic patient tumors, allowing for highly accurate predictions of treatment responses.

Funding

  • EquityFiled Apr 25, 2025Form D
    $19.4M/ $19.4M

Product

MicroOrganoSphere™ (MOS) Technology

Precision Oncology

The MicroOrganoSphere™ (MOS) technology allows the creation of miniature tumor models that preserve the critical biological characteristics of the original tumor. These microscale tumors enable clinicians to test various cancer therapies to determine which are most effective for individual patients.

  • Retains structure and genetic alterations of original tumors
  • Predicts drug response based on patient-specific biology
  • Facilitates high-throughput drug candidate screening

Built for

Oncologists, cancer treatment centers, and pharmaceutical companies

People on file